Grifols SA (GRFS)
7.42
+0.10
(+1.37%)
USD |
NASDAQ |
Jun 11, 14:13
Grifols Research and Development Expense (Quarterly) : 105.29M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 105.29M |
| December 31, 2025 | 159.15M |
| September 30, 2025 | 113.38M |
| June 30, 2025 | 93.69M |
| March 31, 2025 | 101.08M |
| December 31, 2024 | 122.67M |
| September 30, 2024 | 96.54M |
| June 30, 2024 | 73.94M |
| March 31, 2024 | 98.18M |
| December 31, 2023 | 122.12M |
| September 30, 2023 | 96.22M |
| June 30, 2023 | 85.61M |
| March 31, 2023 | 108.25M |
| March 31, 2021 | 86.49M |
| December 31, 2020 | 96.27M |
| September 30, 2020 | 83.40M |
| June 30, 2020 | 81.77M |
| March 31, 2020 | 74.76M |
| December 31, 2019 | 83.07M |
| September 30, 2019 | 76.07M |
| June 30, 2019 | 78.61M |
| March 31, 2019 | 71.09M |
| December 31, 2018 | 80.08M |
| September 30, 2018 | 67.73M |
| June 30, 2018 | 63.48M |
| Date | Value |
|---|---|
| March 31, 2018 | 66.32M |
| December 31, 2017 | 125.31M |
| September 30, 2017 | 70.84M |
| June 30, 2017 | 64.77M |
| March 31, 2017 | 63.07M |
| December 31, 2016 | 48.22M |
| September 30, 2016 | 54.79M |
| June 30, 2016 | 52.46M |
| March 31, 2016 | 48.80M |
| December 31, 2015 | 68.75M |
| September 30, 2015 | 56.39M |
| June 30, 2015 | 54.75M |
| March 31, 2015 | 53.39M |
| December 31, 2014 | 66.47M |
| September 30, 2014 | 56.10M |
| June 30, 2014 | 60.41M |
| March 31, 2014 | 51.92M |
| December 31, 2013 | 41.80M |
| September 30, 2013 | 37.72M |
| June 30, 2013 | 38.08M |
| March 31, 2013 | 38.70M |
| December 31, 2012 | 44.19M |
| September 30, 2012 | 39.59M |
| June 30, 2012 | 38.93M |
| March 31, 2012 | 37.14M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Amarin Corp. Plc | 4.020M |
| Cellectis SA | 23.09M |
| Autolus Therapeutics Plc | 21.17M |
| Akari Therapeutics Plc | 1.457M |
| Evaxion AS | 2.306M |